glp-1 cardiovascular outcomes 2025 news trends 2025: real-world data, patient & future therapies glp-1 cardiovascular outcomes 2025 news

Featured Experts Endocrinology

This effect is more pronounced with short-acting GLP-1 agents and tends to diminish over time with long-acting formulations

Mimicking all three hormones is the reason retatrutide is described as a triple-hormone agonist (a drug that mimics three hormones rather than one or two)

The discounts typically range from 10 to 40 percent off retail, which still leaves significant out-of-pocket costs for expensive medications

Dynamic analysis of metabolomics reveals the potential associations between colonic peptides and serum appetite-related hormones

If you are looking for a clinically proven, regulated weight loss treatment available now, Pharmica offers Mounjaro and Wegovy, both of which are MHRA-approved and dispensed by our registered pharmacists following an online consultation